

## **Devyser completes acquisition of CyberGene AB and carries out issue of compensation shares**

**Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, announces that the acquisition of all shares in CyberGene AB (“CyberGene”) that was announced on 11 February 2026 has today been completed and that closing has occurred. The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin. In connection with closing, Devyser has carried out an issue of compensation shares to the seller Level Bio AB (publ).**

CyberGene develops and markets products in the fields of aneuploidy and male infertility, complementing Devyser’s existing product portfolio. The total purchase consideration amounts to appx. SEK 12.2 million and has been paid through newly issued shares in Devyser.

Devyser, through its wholly-owned subsidiary Devyser AB, on 11 February 2026 entered into a share purchase agreement with Level Bio AB (publ) relating to the acquisition of all shares in CyberGene. The acquisition was conditional upon the receipt of all necessary clearances, approvals, decisions and other actions from the Inspectorate of Strategic Products under the Swedish Screening of Foreign Direct Investments Act. This closing condition has been fulfilled and closing has today, 1 April 2026, been completed.

Cybergene was founded in 1995 and has demonstrated steady growth driven by a strong product offering and consistent market expansion. Devyser and Cybergene have been active in similar markets for many years, providing Devyser with in-depth knowledge of Cybergene’s products and their strong customer acceptance.

The acquisition is consolidated from and including 1 April 2026 and is expected to have a positive impact on Devyser’s gross profit as well as EBIT.

As previously announced, the acquisition is fully financed through a directed issue of new shares in Devyser to Level Bio AB (publ), to be paid by way of set-off against the seller’s claim on the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors today resolved upon an issue of 124,363 new shares in Devyser, entitling Level Bio AB (publ), as the seller of CyberGene, to subscribe for the new shares. The subscription price corresponds to the volume-weighted average price (VWAP) of the Devyser share on Nasdaq First North Premier Growth Market during the ten (10) trading days following and including 11 February 2026 and amounts to approximately SEK 98.29 per share. Level Bio AB (publ) has subscribed for all 124,363 shares and the share issue corresponds to a dilution of approximately 0.74 per cent of all shares and votes in Devyser. Following the share issue, the total share capital in Devyser amounts to approximately SEK 963,497.29 and the total number of shares and votes amounts to 16,788,555.



**PRESS RELEASE**  
01 April 2026 10:15:00 CEST

**For more information, please contact:**

Jan Wahlström, CEO

Email: [ir@devyser.com](mailto:ir@devyser.com)

Telephone: +46 8 562 158 50

Sabina Berlin, CFO

Email: [ir@devyser.com](mailto:ir@devyser.com)

Telephone: +46 8 562 158 50

**About Devyser**

Devyser is redefining how laboratories approach genetic testing. As your true one-stop shop, we offer streamlined solutions for a wide range of conditions, helping labs overcome complexity, reduce turnaround times, and maximize efficiency.

Our technologies simplify workflows, minimize hands-on time, and deliver fast, accurate results. Every test is designed to empower labs to do more with less, freeing up resources while supporting better patient outcomes.

We specialize in diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories - two critical areas where accuracy and speed matter. With customers in 65+ countries, we also operate our own CLIA-certified laboratory, Devyser Genomic Laboratories, in Atlanta and maintain sales offices across Europe and the US.

Devyser is committed to regulatory excellence under IVDR, ensuring the highest quality standards across our growing product portfolio.

Founded in 2004 and headquartered in Stockholm, Devyser is listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). Redeye Nordic Growth AB is the company's Certified Adviser.

Discover how we're shaping the future of lab diagnostics at [www.devyser.com](http://www.devyser.com).